Two small doses of a compound best known as a psychedelic may quietly hold the key to sparing cancer patients some of the cruelest side effects of chemotherapy. Researchers at The University of Texas MD Anderson Cancer Center in Houston found that giving psilocybin before chemo prevented nerve injury in lab models — even when treatment was repeated again and again. The discovery, published in Science, points toward a way to stop the pain, numbness, and loss of sensation that millions of chemotherapy patients endure, sometimes for the rest of their lives.
Here is why this matters. Chemotherapy saves lives, but it can damage healthy cells too, including the nerves of the peripheral nervous system — the wiring that runs through your arms and legs. That damage, called peripheral neuropathy, can cause burning pain, sensitivity to cold, numbness, and trouble with balance. For some patients, it becomes so bad they cannot continue their lifesaving treatment at all. And once established, this kind of nerve injury is often permanent; existing treatments help only a little.
The MD Anderson team, co-led by Dr. Moran Amit, professor of Head and Neck Surgery, and Dr. Patrick Dougherty, professor of Pain Medicine, uncovered something unexpected. Psilocybin does not just act on the brain. It directly reaches the peripheral nerves through a receptor called serotonin 5-HT2A. In their models, as few as two doses given before chemotherapy protected sensory nerve endings, preserved touch sensation, and stopped the hypersensitivity to cold — all while keeping the chemotherapy's ability to fight tumors fully intact)Skip. The protection held up across repeated rounds of three common chemo drugs: cisplatin, paclitaxel, and docetaxel.
The team also found a reason this works. Chemotherapy was zapping mitochondria, the tiny energy factories inside cells, and slowing their movement along nerve fibers. Psilocybin switched on a signaling pathway that kept that energy delivery running, so nerve endings had the fuel they needed to survive. When the researchers blocked the 5-HT2A receptor, the protection vanished. A nonhallucinogenic compound that activates the same receptor worked just like psilocybin — raising the possibility of a protective treatment without the psychedelic effects.
"There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy," said Amit. Psilocybin, he added, protects nerves before damage occurs "rather than treating symptoms after they become persistent."
Dougherty put it simply: psilocybin does more than muffle pain signals — it protects the nerves themselves through energy delivery, helping patients hold onto sensation, mobility, and quality of life during treatment and far into survivorship.
This is not science fiction destined to stay in a lab. The findings are the foundation for an upcoming phase 2 clinical trial called NeuroGuard (NCT07227909), which will test psilocybin during chemotherapy in patients with several cancer types. It is part of MD Anderson's broader Cancer Neuroscience Program, exploring how cancer and the nervous system talk to each other. If the trial succeeds, a medicine long associated with altered states could become something else entirely: a gentle shield for people fighting for their lives.